Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 74 entries
Sorted by: Best Match Show Resources per page
Paraneoplastic syndromes in olfactory neuroblastoma.

Contemporary oncology (Poznan, Poland)

Kunc M, Gabrych A, Czapiewski P, Sworczak K.
PMID: 26199564
Contemp Oncol (Pozn). 2015;19(1):6-16. doi: 10.5114/wo.2015.46283. Epub 2015 Mar 26.

Olfactory neuroblastoma (ONB) is a rare malignant neoplasm of sinonasal tract, derived from olfactory epithelium. Unilateral nasal obstruction, epistaxis, sinusitis, and headaches are common symptoms. Olfactory neuroblastoma shows neuroendocrine differentiation and similarly to other neuroendocrine tumors can produce several...

Cite
Kunc M, Gabrych A, Czapiewski P, et al. Paraneoplastic syndromes in olfactory neuroblastoma. Contemp Oncol (Pozn). 2015;19(1):6-16doi: 10.5114/wo.2015.46283.
Kunc, M., Gabrych, A., Czapiewski, P., & Sworczak, K. (2015). Paraneoplastic syndromes in olfactory neuroblastoma. Contemporary oncology (Poznan, Poland), 19(1), 6-16. https://doi.org/10.5114/wo.2015.46283
Kunc, Michał, et al. "Paraneoplastic syndromes in olfactory neuroblastoma." Contemporary oncology (Poznan, Poland) vol. 19,1 (2015): 6-16. doi: https://doi.org/10.5114/wo.2015.46283
Kunc M, Gabrych A, Czapiewski P, Sworczak K. Paraneoplastic syndromes in olfactory neuroblastoma. Contemp Oncol (Pozn). 2015;19(1):6-16. doi: 10.5114/wo.2015.46283. Epub 2015 Mar 26. PMID: 26199564; PMCID: PMC4507891.
Copy Download .nbib Format: NLM
The posterior communicating artery: morphometric study in 3D angio-computed tomography reconstruction. The proof of the mathematical definition of the hypoplasia.

Folia morphologica

Dzierżanowski J, Szarmach A, Słoniewski P, Czapiewski P, Piskunowicz M, Bandurski T, Szmuda T.
PMID: 25242155
Folia Morphol (Warsz). 2014 Aug;73(3):286-91. doi: 10.5603/FM.2014.0045.

BACKGROUND: The aim of this study was to investigate the morphometry of the posterior communicating artery (PCoA), on the basis of angio-computed tomography (CT), and to give proof of the mathematical definition of the term "hypopal sia of the...

Cite
Dzierżanowski J, Szarmach A, Słoniewski P, et al. The posterior communicating artery: morphometric study in 3D angio-computed tomography reconstruction. The proof of the mathematical definition of the hypoplasia. Folia Morphol (Warsz). 2014;73(3):286-91doi: 10.5603/FM.2014.0045.
Dzierżanowski, J., Szarmach, A., Słoniewski, P., Czapiewski, P., Piskunowicz, M., Bandurski, T., & Szmuda, T. (2014). The posterior communicating artery: morphometric study in 3D angio-computed tomography reconstruction. The proof of the mathematical definition of the hypoplasia. Folia morphologica, 73(3), 286-91. https://doi.org/10.5603/FM.2014.0045
Dzierżanowski, J, et al. "The posterior communicating artery: morphometric study in 3D angio-computed tomography reconstruction. The proof of the mathematical definition of the hypoplasia." Folia morphologica vol. 73,3 (2014): 286-91. doi: https://doi.org/10.5603/FM.2014.0045
Dzierżanowski J, Szarmach A, Słoniewski P, Czapiewski P, Piskunowicz M, Bandurski T, Szmuda T. The posterior communicating artery: morphometric study in 3D angio-computed tomography reconstruction. The proof of the mathematical definition of the hypoplasia. Folia Morphol (Warsz). 2014 Aug;73(3):286-91. doi: 10.5603/FM.2014.0045. PMID: 25242155.
Copy Download .nbib Format: NLM
Reproductive and Behavior Dysfunction Induced by Maternal Androgen Exposure and Obesity Is Likely Not Gut Microbiome-Mediated.

Journal of the Endocrine Society

Lindheim L, Manti M, Fornes R, Bashir M, Czarnewski P, Diaz OE, Seifert M, Engstrand L, Villablanca EJ, Obermayer-Pietsch B, Stener-Victorin E.
PMID: 30534630
J Endocr Soc. 2018 Oct 15;2(12):1363-1380. doi: 10.1210/js.2018-00266. eCollection 2018 Dec 01.

Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder of unclear etiology in women and is characterized by androgen excess, insulin resistance, and mood disorders. The gut microbiome is known to influence conditions closely related with PCOS,...

Cite
Lindheim L, Manti M, Fornes R, et al. Reproductive and Behavior Dysfunction Induced by Maternal Androgen Exposure and Obesity Is Likely Not Gut Microbiome-Mediated. J Endocr Soc. 2018;2(12):1363-1380doi: 10.1210/js.2018-00266.
Lindheim, L., Manti, M., Fornes, R., Bashir, M., Czarnewski, P., Diaz, O. E., Seifert, M., Engstrand, L., Villablanca, E. J., Obermayer-Pietsch, B., & Stener-Victorin, E. (2018). Reproductive and Behavior Dysfunction Induced by Maternal Androgen Exposure and Obesity Is Likely Not Gut Microbiome-Mediated. Journal of the Endocrine Society, 2(12), 1363-1380. https://doi.org/10.1210/js.2018-00266
Lindheim, Lisa, et al. "Reproductive and Behavior Dysfunction Induced by Maternal Androgen Exposure and Obesity Is Likely Not Gut Microbiome-Mediated." Journal of the Endocrine Society vol. 2,12 (2018): 1363-1380. doi: https://doi.org/10.1210/js.2018-00266
Lindheim L, Manti M, Fornes R, Bashir M, Czarnewski P, Diaz OE, Seifert M, Engstrand L, Villablanca EJ, Obermayer-Pietsch B, Stener-Victorin E. Reproductive and Behavior Dysfunction Induced by Maternal Androgen Exposure and Obesity Is Likely Not Gut Microbiome-Mediated. J Endocr Soc. 2018 Oct 15;2(12):1363-1380. doi: 10.1210/js.2018-00266. eCollection 2018 Dec 01. PMID: 30534630; PMCID: PMC6280317.
Copy Download .nbib Format: NLM
Trial Proteomic Qualitative and Quantitative Analysis of the Protein Matrix of Submandibular Sialoliths.

Molecules (Basel, Switzerland)

Czaplewska P, Bogucka AE, Musiał N, Tretiakow D, Skorek A, Stodulski D.
PMID: 34771131
Molecules. 2021 Nov 06;26(21). doi: 10.3390/molecules26216725.

Our studies aimed to explore the protein components of the matrix of human submandibular gland sialoliths. A qualitative analysis was carried out based on the filter aided sample preparation (FASP) methodology. In the protein extraction process, we evaluated the...

Cite
Czaplewska P, Bogucka AE, Musiał N, et al. Trial Proteomic Qualitative and Quantitative Analysis of the Protein Matrix of Submandibular Sialoliths. Molecules. 2021;26(21)doi: 10.3390/molecules26216725.
Czaplewska, P., Bogucka, A. E., Musiał, N., Tretiakow, D., Skorek, A., & Stodulski, D. (2021). Trial Proteomic Qualitative and Quantitative Analysis of the Protein Matrix of Submandibular Sialoliths. Molecules (Basel, Switzerland), 26(21), . https://doi.org/10.3390/molecules26216725
Czaplewska, Paulina, et al. "Trial Proteomic Qualitative and Quantitative Analysis of the Protein Matrix of Submandibular Sialoliths." Molecules (Basel, Switzerland) vol. 26,21 (2021). doi: https://doi.org/10.3390/molecules26216725
Czaplewska P, Bogucka AE, Musiał N, Tretiakow D, Skorek A, Stodulski D. Trial Proteomic Qualitative and Quantitative Analysis of the Protein Matrix of Submandibular Sialoliths. Molecules. 2021 Nov 06;26(21). doi: 10.3390/molecules26216725. PMID: 34771131; PMCID: PMC8588320.
Copy Download .nbib Format: NLM
Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab.

Oncology letters

Villalobos M, Czapiewski P, Reinmuth N, Fischer JR, Andreas S, Kortsik C, Serke M, Wolf M, Neuser P, Reuss A, Schnabel PA, Thomas M.
PMID: 31186697
Oncol Lett. 2019 Jun;17(6):4891-4900. doi: 10.3892/ol.2019.10153. Epub 2019 Mar 15.

The aim of the present study was to assess the expression of epithelial-mesenchymal transition biomarkers (E-cadherin and vimentin) and their potential significance as prognostic markers in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) enrolled in the...

Cite
Villalobos M, Czapiewski P, Reinmuth N, et al. Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab. Oncol Lett. 2019;17(6):4891-4900doi: 10.3892/ol.2019.10153.
Villalobos, M., Czapiewski, P., Reinmuth, N., Fischer, J. R., Andreas, S., Kortsik, C., Serke, M., Wolf, M., Neuser, P., Reuss, A., Schnabel, P. A., & Thomas, M. (2019). Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab. Oncology letters, 17(6), 4891-4900. https://doi.org/10.3892/ol.2019.10153
Villalobos, Matthias, et al. "Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab." Oncology letters vol. 17,6 (2019): 4891-4900. doi: https://doi.org/10.3892/ol.2019.10153
Villalobos M, Czapiewski P, Reinmuth N, Fischer JR, Andreas S, Kortsik C, Serke M, Wolf M, Neuser P, Reuss A, Schnabel PA, Thomas M. Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab. Oncol Lett. 2019 Jun;17(6):4891-4900. doi: 10.3892/ol.2019.10153. Epub 2019 Mar 15. PMID: 31186697; PMCID: PMC6507446.
Copy Download .nbib Format: NLM
A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures.

Cannabis and cannabinoid research

Brodie MJ, Czapinski P, Pazdera L, Sander JW, Toledo M, Napoles M, Sahebkar F, Schreiber A.
PMID: 33998885
Cannabis Cannabinoid Res. 2021 Dec;6(6):528-536. doi: 10.1089/can.2020.0075. Epub 2021 Feb 15.

No abstract available.

Cite
Brodie MJ, Czapinski P, Pazdera L, et al. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res. 2021;6(6):528-536doi: 10.1089/can.2020.0075.
Brodie, M. J., Czapinski, P., Pazdera, L., Sander, J. W., Toledo, M., Napoles, M., Sahebkar, F., Schreiber, A. (2021). A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis and cannabinoid research, 6(6), 528-536. https://doi.org/10.1089/can.2020.0075
Brodie, Martin J, et al. "A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures." Cannabis and cannabinoid research vol. 6,6 (2021): 528-536. doi: https://doi.org/10.1089/can.2020.0075
Brodie MJ, Czapinski P, Pazdera L, Sander JW, Toledo M, Napoles M, Sahebkar F, Schreiber A. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res. 2021 Dec;6(6):528-536. doi: 10.1089/can.2020.0075. Epub 2021 Feb 15. PMID: 33998885.
Copy Download .nbib Format: NLM
EDEM1 Regulates Amyloid Precursor Protein (APP) Metabolism and Amyloid-β Production.

International journal of molecular sciences

Nowakowska-Gołacka J, Czapiewska J, Sominka H, Sowa-Rogozińska N, Słomińska-Wojewódzka M.
PMID: 35008544
Int J Mol Sci. 2021 Dec 23;23(1). doi: 10.3390/ijms23010117.

Endoplasmic reticulum (ER) degradation-enhancing α-mannosidase-like protein 1 (EDEM1) is a quality control factor directly involved in the endoplasmic reticulum-associated degradation (ERAD) process. It recognizes terminally misfolded proteins and directs them to retrotranslocation which is followed by proteasomal degradation in...

Cite
Nowakowska-Gołacka J, Czapiewska J, Sominka H, et al. EDEM1 Regulates Amyloid Precursor Protein (APP) Metabolism and Amyloid-β Production. Int J Mol Sci. 2021;23(1)doi: 10.3390/ijms23010117.
Nowakowska-Gołacka, J., Czapiewska, J., Sominka, H., Sowa-Rogozińska, N., & Słomińska-Wojewódzka, M. (2021). EDEM1 Regulates Amyloid Precursor Protein (APP) Metabolism and Amyloid-β Production. International journal of molecular sciences, 23(1), . https://doi.org/10.3390/ijms23010117
Nowakowska-Gołacka, Jowita, et al. "EDEM1 Regulates Amyloid Precursor Protein (APP) Metabolism and Amyloid-β Production." International journal of molecular sciences vol. 23,1 (2021). doi: https://doi.org/10.3390/ijms23010117
Nowakowska-Gołacka J, Czapiewska J, Sominka H, Sowa-Rogozińska N, Słomińska-Wojewódzka M. EDEM1 Regulates Amyloid Precursor Protein (APP) Metabolism and Amyloid-β Production. Int J Mol Sci. 2021 Dec 23;23(1). doi: 10.3390/ijms23010117. PMID: 35008544.
Copy Download .nbib Format: NLM
Single-cell BCR and transcriptome analysis after influenza infection reveals spatiotemporal dynamics of antigen-specific B cells.

Cell reports

Mathew NR, Jayanthan JK, Smirnov IV, Robinson JL, Axelsson H, Nakka SS, Emmanouilidi A, Czarnewski P, Yewdell WT, Schön K, Lebrero-Fernández C, Bernasconi V, Rodin W, Harandi AM, Lycke N, Borcherding N, Yewdell JW, Greiff V, Bemark M, Angeletti D.
PMID: 34161770
Cell Rep. 2021 Jun 22;35(12):109286. doi: 10.1016/j.celrep.2021.109286.

B cell responses are critical for antiviral immunity. However, a comprehensive picture of antigen-specific B cell differentiation, clonal proliferation, and dynamics in different organs after infection is lacking. Here, by combining single-cell RNA and B cell receptor (BCR) sequencing...

Cite
Mathew NR, Jayanthan JK, Smirnov IV, et al. Single-cell BCR and transcriptome analysis after influenza infection reveals spatiotemporal dynamics of antigen-specific B cells. Cell Rep. 2021;35(12):109286doi: 10.1016/j.celrep.2021.109286.
Mathew, N. R., Jayanthan, J. K., Smirnov, I. V., Robinson, J. L., Axelsson, H., Nakka, S. S., Emmanouilidi, A., Czarnewski, P., Yewdell, W. T., Schön, K., Lebrero-Fernández, C., Bernasconi, V., Rodin, W., Harandi, A. M., Lycke, N., Borcherding, N., Yewdell, J. W., Greiff, V., Bemark, M., & Angeletti, D. (2021). Single-cell BCR and transcriptome analysis after influenza infection reveals spatiotemporal dynamics of antigen-specific B cells. Cell reports, 35(12), 109286. https://doi.org/10.1016/j.celrep.2021.109286
Mathew, Nimitha R, et al. "Single-cell BCR and transcriptome analysis after influenza infection reveals spatiotemporal dynamics of antigen-specific B cells." Cell reports vol. 35,12 (2021): 109286. doi: https://doi.org/10.1016/j.celrep.2021.109286
Mathew NR, Jayanthan JK, Smirnov IV, Robinson JL, Axelsson H, Nakka SS, Emmanouilidi A, Czarnewski P, Yewdell WT, Schön K, Lebrero-Fernández C, Bernasconi V, Rodin W, Harandi AM, Lycke N, Borcherding N, Yewdell JW, Greiff V, Bemark M, Angeletti D. Single-cell BCR and transcriptome analysis after influenza infection reveals spatiotemporal dynamics of antigen-specific B cells. Cell Rep. 2021 Jun 22;35(12):109286. doi: 10.1016/j.celrep.2021.109286. PMID: 34161770.
Copy Download .nbib Format: NLM
A novel approach exploiting properties of convolutional neural networks for vessel movement anomaly detection and classification.

ISA transactions

Czaplewski B, Dzwonkowski M.
PMID: 33653511
ISA Trans. 2022 Jan;119:1-16. doi: 10.1016/j.isatra.2021.02.030. Epub 2021 Feb 22.

The article concerns the automation of vessel movement anomaly detection for maritime and coastal traffic safety services. Deep Learning techniques, specifically Convolutional Neural Networks (CNNs), were used to solve this problem. Three variants of the datasets, containing samples of...

Cite
Czaplewski B, Dzwonkowski M. A novel approach exploiting properties of convolutional neural networks for vessel movement anomaly detection and classification. ISA Trans. 2021;119:1-16doi: 10.1016/j.isatra.2021.02.030.
Czaplewski, B., & Dzwonkowski, M. (2022). A novel approach exploiting properties of convolutional neural networks for vessel movement anomaly detection and classification. ISA transactions, 1191-16. https://doi.org/10.1016/j.isatra.2021.02.030
Czaplewski, Bartosz, and Dzwonkowski, Mariusz. "A novel approach exploiting properties of convolutional neural networks for vessel movement anomaly detection and classification." ISA transactions vol. 119 (2022): 1-16. doi: https://doi.org/10.1016/j.isatra.2021.02.030
Czaplewski B, Dzwonkowski M. A novel approach exploiting properties of convolutional neural networks for vessel movement anomaly detection and classification. ISA Trans. 2022 Jan;119:1-16. doi: 10.1016/j.isatra.2021.02.030. Epub 2021 Feb 22. PMID: 33653511.
Copy Download .nbib Format: NLM
A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures.

Cannabis and cannabinoid research

Brodie MJ, Czapinski P, Pazdera L, Sander JW, Toledo M, Napoles M, Sahebkar F, Schreiber A.
PMID: 33998885
Cannabis Cannabinoid Res. 2021 Dec;6(6):528-536. doi: 10.1089/can.2020.0075. Epub 2021 Feb 15.

No abstract available.

Cite
Brodie MJ, Czapinski P, Pazdera L, et al. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res. 2021;6(6):528-536doi: 10.1089/can.2020.0075.
Brodie, M. J., Czapinski, P., Pazdera, L., Sander, J. W., Toledo, M., Napoles, M., Sahebkar, F., Schreiber, A. (2021). A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis and cannabinoid research, 6(6), 528-536. https://doi.org/10.1089/can.2020.0075
Brodie, Martin J, et al. "A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures." Cannabis and cannabinoid research vol. 6,6 (2021): 528-536. doi: https://doi.org/10.1089/can.2020.0075
Brodie MJ, Czapinski P, Pazdera L, Sander JW, Toledo M, Napoles M, Sahebkar F, Schreiber A. A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis Cannabinoid Res. 2021 Dec;6(6):528-536. doi: 10.1089/can.2020.0075. Epub 2021 Feb 15. PMID: 33998885; PMCID: PMC8713263.
Copy Download .nbib Format: NLM
[No title available]

Contemporary oncology (Poznan, Poland)

Kunc M, Gabrych A, Rekawiecki B, Gorczynski A, Franke S, Haybaeck J, Biernat W, Czapiewski P.
PMID: 31992951
Contemp Oncol (Pozn). 2019;23(4):202-207. doi: 10.5114/wo.2019.89635. Epub 2019 Nov 07.

INTRODUCTION: Carcinosarcoma (CS) is an infrequent neoplasm composed of a carcinomatous and a sarcomatous element. Its molecular pathogenesis is poorly understood. In this study, we investigated the disturbances in the immunohistochemical expression of p53 and mismatch repair (MMR) proteins,...

Cite
Kunc M, Gabrych A, Rekawiecki B, et al. . Contemp Oncol (Pozn). 2019;23(4):202-207doi: 10.5114/wo.2019.89635.
Kunc, M., Gabrych, A., Rekawiecki, B., Gorczynski, A., Franke, S., Haybaeck, J., Biernat, W., & Czapiewski, P. (2019). . Contemporary oncology (Poznan, Poland), 23(4), 202-207. https://doi.org/10.5114/wo.2019.89635
Kunc, Michal, et al. "." Contemporary oncology (Poznan, Poland) vol. 23,4 (2019): 202-207. doi: https://doi.org/10.5114/wo.2019.89635
Kunc M, Gabrych A, Rekawiecki B, Gorczynski A, Franke S, Haybaeck J, Biernat W, Czapiewski P. . Contemp Oncol (Pozn). 2019;23(4):202-207. doi: 10.5114/wo.2019.89635. Epub 2019 Nov 07. PMID: 31992951; PMCID: PMC6978758.
Copy Download .nbib Format: NLM
The predictive potential of Neuronatin for neoadjuvant chemotherapy of breast cancer.

Cancer biomarkers : section A of Disease markers

Pieper W, Ignatov A, Kalinski T, Haybaeck J, Czapiewski P, Nass N.
PMID: 34092612
Cancer Biomark. 2021;32(2):161-173. doi: 10.3233/CBM-203127.

BACKGROUND: Neuronatin (NNAT) determined by immunohistochemistry is a negative prognostic biomarker for breast cancer, independent of the major clinicopathological markers.OBJECTIVE: Here, we investigated whether NNAT is also a predictive biomarker for pathological remission after neoadjuvant chemotherapy.METHODS: One hundred and...

Cite
Pieper W, Ignatov A, Kalinski T, et al. The predictive potential of Neuronatin for neoadjuvant chemotherapy of breast cancer. Cancer Biomark. 2021;32(2):161-173doi: 10.3233/CBM-203127.
Pieper, W., Ignatov, A., Kalinski, T., Haybaeck, J., Czapiewski, P., & Nass, N. (2021). The predictive potential of Neuronatin for neoadjuvant chemotherapy of breast cancer. Cancer biomarkers : section A of Disease markers, 32(2), 161-173. https://doi.org/10.3233/CBM-203127
Pieper, Willi, et al. "The predictive potential of Neuronatin for neoadjuvant chemotherapy of breast cancer." Cancer biomarkers : section A of Disease markers vol. 32,2 (2021): 161-173. doi: https://doi.org/10.3233/CBM-203127
Pieper W, Ignatov A, Kalinski T, Haybaeck J, Czapiewski P, Nass N. The predictive potential of Neuronatin for neoadjuvant chemotherapy of breast cancer. Cancer Biomark. 2021;32(2):161-173. doi: 10.3233/CBM-203127. PMID: 34092612.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 74 entries